Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

Arvelle Therapeutics GmbH

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. *

 

Period Start 2019-02-14 established (approx)
Products Industry CNS drug
  Industry 2 cenobamate
Person Person Altmeyer, Mark (Arvelle Therapeutics 201902– CEO before Axovant Sciences + BMS + Otsuka America Pharmaceutical)
     
Region Region Basel BS
  Country Switzerland
  Street 8 Viaduktstr.
  City 4051 Basel BS
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel.
     
   
Record changed: 2020-09-26

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Arvelle Therapeutics GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top